Yissum - Research Development Company of the Hebrew University

Decoy-Oligonucleotides Inhibiting RNA-Binding Proteins for Treatment of Cancer

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster8
A new technology of decoy oligonucleotide ( modified RNA) to inhibit the activity of RNA binding proteins ( splicing factors) by competition with their natural target .
RNA / DNA therapy
Project ID : 6-2015-3107

Description of the technology

Categories

Treatment of cancer, neurodegeneration and infectious diseases.

Development Stage

In vitro proof of concept; in vivo POC

Patent Status

PCT publication number : WO2016/142948

Highlights

  • A new technology to inhibit the activity of RNA binding proteins.
  • Inhibition of oncogenic splicing factors inhibits cancer cells in cell culture and in animals.
  • Ability to design specific inhibitors to a variety of splicing factors involved in multiple diseases.
  • Lower toxicity than available knockdown technologies.

Our Innovation

Currently there are no molecules that can directly inhibit the activity of splicing factors. We created decoy oligonucleotides that directly bind and inhibit the splicing activity of splicing factors without affecting their expression or protein-protein interactions. These unique oligos are superior to knockdown technologies (RNAi, antisense oligonucleotides) as they directly bind to the target protein, are not dependent on the half-life of the target protein and are independent of cellular machineries (e.g. RNAi) which can be mutated or are absent in certain cancers or organisms.

Clinical Implications

Any disease with elevated activity of splicing factors including cancer, neurological conditions, neurodegenerative diseases, viral infections and others.

Key Features

  • Decoy oligonucleotides that inhibit specific splicing factors can be used to treat cancer and other diseases.
  • Decoy oligonucleotides against a specific oncogenic splicing factor inhibits the oncogenic properties of breast, lung, pancreatic, and glioblastoma cancer cells.
  • Intellectual property includes potential decoys for over 30 splicing factors for the treatment of different diseases.
  • Decoy technology is superior to knockdown techniques as it is direct, independent of cellular machineries, and less toxic than current knockdown technologies which eliminate the target protein.

Development Milestones

Proof of concept demonstrated for three different splicing factors in cell culture and for two splicing factors also in animals.

Decoy against an oncogenic splicing factor inhibited metastatic breast cancer and glioblastoma in cell culture and in animals.

The Opportunity

A new platform to inhibit splicing factors for the treatment of several diseases. The IP includes multiple possible sequences, against more than 30 different splicing factors, including

decoy oligonucleotides against splicing factors mutated in certain cancers.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Rotem Karni
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.